FDA Archives

Diamond Shruumz Recall Escalates: FDA Links Microdosing Products to Severe Illnesses and Two Deaths

WASHINGTON — Federal regulators are intensifying their scrutiny of Diamond Shruumz, a popular brand of microdosing products, following a link to numerous illnesses and two potential deaths across the United States. The Food and Drug Administration (FDA) announced the brand’s comprehensive recall of its chocolate bars, infused cones, and gummy products, all of which are marketed as enhancing creativity and mental health benefits. The probe escalates as adverse reports mount, with the FDA citing 74 …

FDA Probes Link Between Diamond Shruumz Edibles and Mysterious Deaths Amid Widespread Illness Reports

Washington, D.C. — The Food and Drug Administration (FDA) has launched a detailed investigation following reports that microdosing products by Diamond Shruumz could be linked to severe illnesses and even two fatalities. The company, which had previously issued a recall for these products in June, is now under scrutiny as the cases have escalated to national concern. Earlier this week, the FDA updated the public on the situation, revealing that a total of 74 people …

FDA Probes Two Deaths and Multiple Illnesses Linked to Recalled Microdosing Products from Diamond Shruumz

WASHINGTON — The Food and Drug Administration is currently probing the link between products from Diamond Shruumz, a company known for its “microdose” edibles, and a series of adverse health events including two deaths. The company had previously recalled its products in June after reports of illnesses began to surface across various states. As of late July, the FDA has received reports of 74 illnesses across 28 states related to the consumption of Diamond Shruumz …

FDA Advisers Endorse Carvykti and Abecma for Earlier Use, Despite Early Death Concerns

Washington, DC – After concerns about potential early deaths, the FDA advisers have endorsed J&J and Legend’s Carvykti, as well as BMS’ Abecma for use in earlier stages of treatment. Despite initial worries, the FDA advisory committee has ultimately given their support to the new treatment options. Carvykti, a drug developed by Johnson & Johnson and Legend Biotech, and Abecma, from Bristol Myers Squibb, have received approval for earlier use in certain circumstances. This decision …

FDA Panel Votes to Support CAR-T Therapies by Johnson & Johnson and Bristol Myers Squibb for Multiple Myeloma Treatment

Silver Spring, Maryland – An FDA advisory committee voted overwhelmingly in favor of recommending the approval of CAR-T therapies from Johnson & Johnson, Legend Biotech, Bristol Myers Squibb, and 2seventyBio for the treatment of multiple myeloma. The committee’s support for these therapies highlights a significant milestone in the ongoing discussions surrounding the use of CAR-T treatments in cancer care. During the committee meeting, concerns were raised about the higher rate of early deaths observed in …